Pharmacology and toxicology Flashcards
(101 cards)
Agents for CCB and beta blocker OD
• Atropine 1mg stat (can be repeated x 3; often ineffective; muscarinic receptor
antagonist increases SA node discharge, conduction through the AV node and opposes
action of Vagus nerve)
• Adrenaline or Noradrenaline infusion starting at 10-20 g/min and titrate to a MAP > 65
mmHg (+ve inotropy, chronotropy, vasoconstriction)
• Calcium – Chloride or Gluconate can be given (more calcium in CaCl) – 10mls of 10%
solution (can be repeated x3 +/- infusion; competitively increases calcium entry into the
myocardium via non-blocked channels)
• Glucagon 5mg stat (can be repeated x3; increases intracellular cAMP and has been
shown to increase heart rate in BOTH beta-blocker and CCB toxicity).
• 100mls 8.4% NaHCO3 stat (she is already very acidotic)
• Hyperinsulinaemia-Euglycaemia – short acting insulin 1 unit/kg with 50mls 50%
Dextrose bolus, then 0.5 units insulin /kg/hr with 10% dextrose infusion and q1hrly BGLs
and K+ (high dose insulin = +ve inotrope but mechanism not clearly understood)
• Lipid Emulsion – 1ml/kg 20% lipid emulsion bolus (can be repeated x 3 then start
infusion 0.5mls/kg/min; acts as a “lipid sink” surrounding lipophillic drugs rendering them
ineffective & maybe fatty energy source for myocardium)
Theophilline overdose
Symptoms Nausea Vomiting Elevated mood Agitation, anxiety Hallucinations
Signs - Tachypnoea Tachycardia Hypotension Widened pulse pressure Tremor Seizures Increased muscle tone Fasciculations
Biochemistry - Hypokalemia Hypomagnesemia Hypophosphataemia Hyperglycaemia Hypercalcemia Lactic acidosis Respiratory alkalosis Rhabdomyolysis
Management of theophilline overdose
Decontamination
Repeated doses of activated charcoal (MDAC)
Enhanced elimination
Charcoal haemoperfusion
Antidotes
Strangely, SVT does not respond to adenosine. Goldfranks’ Manual (2007 edition, p. 557) recommends calcium channel blockers as a more effective antiarrhythmic therapy (a β-blocker would be just as good but the patient will inevitably be somebody with either asthma or COPD).
Supportive management
Complications of salycilate toxicity
pulmonary oedema cerebral ordema myocardial depression and shock hypoglycaemia seizures haemorrhage from gastric ulceration muscle rigidity leading to respiratory depression
Haemotological changes in salycilate toxicity
Raised PT: The classical coagulopathy which develops (asked about in the SAQs) is a prothrombin deficiency, leading to a prolonged PT and increased INR.
- because of hepatotoxicity and interference with the synthesis of vitamin K dependent factors.
Platelet dysfunction (due to COX enzyme inhibition)
Haemolytic anaemia (either by an autouimmune mechanism similar to that of methyldopa, or by oxidative damage as in G6PD).
options for enhancing salicylate removal
Haemodialysis. Most of the drug is protein-bound, and is concentration dependant. The volume of distribution is small, and binding site saturation leads to large levels of free drug, which is easily dialyzable
Multiple-dose charcoal. Many aspirin forms are slow release and after ingestion they clump together in the GI tract, forming a large slow release preparation. It is also poorly soluble in the stomach leading to delayed absorption.
Forced alkaline diuresis. Renal excretion of salicylates becomes important when the metabolic pathways become saturated. There is a 10 – 20 x increase in elimination when the urine pH increased from 5 – 8. Current role is questionable as haemodialysis is more efficient at removal, with less metabolic disturbance. Reasonable, as initial therapy whilst waiting for circuit prime and line insertion.
Salicylate level may be declining because -
It is clearing renally or by hepatic metabolism
Absorption from a bezoar is diminishing
The intracellular uptake of salycilate has resulted in decreased serum levels
It may indicate that the drug is moving into the tissues, and not necessarily being eliminated - This means that clinical assessment is paramount
Issues specific to substance ingestion in 2 year old
Ingested agent likely to be non-pharmaceutical
Vast majority of ingestions are benign
Other children may be affected (siblings, playmates)
Doses ingested likely to be small (2-3 tablets or small handful) and toxic effects mg/kg the same as adults but some agents can be potentially lethal for a toddler if even 1-2 tablets taken (e.g. amphetamines, Ca channel blockers, sulphonylureas) or a mouthful (e.g. organophosphate insecticides, eucalyptus oil, one mothball)
Unlikely to obtain accurate dosing history – risk assessment and management based on “worst-case scenario”
Need admission to health care facility with resources for paediatric resuscitation
Regular check of blood sugar levels
Usual toxicology screening tests for adult patient not necessary
GI decontamination with activated charcoal is not routine because of increased risks with aspiration – reserved for severe or life-threatening poisoning where supportive care or antidote treatment alone is inadequate
If severe intoxication suggesting large, repeated or unusual exposure, consider NAI
Issues specific to substance ingestion in 30/40
Risks to mother and foetus
Pregnancy-induced physiological changes impact on drug pharmacokinetics
Delayed gastric absorption and GI transit time slows drug absorption and increases period of potential benefit for decontamination
Increased blood volume increases VD and decreases drug plasma levels
Dilution of plasma proteins increases free drug levels
Hepatic enzyme systems altered by circulating hormones
Increased cardiac output increase renal blood flow and GFR
Hypovolaemia and respiratory compromise may go unrecognised until at a late stage
A few agents pose increased risk to foetus and treatment threshold is lowered (e.g.
salicylates, CO, lead, MetHb-inducing agents)
Excellence in supportive care for the mother ensures best outcome for foetus
Obstetric and neonatal as well as toxicology input needed including decision for emergency delivery of baby.
Issues specific to substance ingestion in 75-year-old adult with chronic kidney disease
Limited physiological reserve, deteriorating cognition, multiple co-morbidities and polypharmacy lead to exaggerated and unpredictable response in poisoning
More severe clinical course for same dose of same agent taken by healthy young adult
Pharmacokinetic changes with ageing and CKD o Delayed GI absorption o Decreased protein binding and increased free drug levels o Reduced liver function with decreased drug metabolism o Reduced renal function and reduced elimination o Baseline CKD likely to be made worse o “Therapeutic” drug doses may be toxic
Pharmacodynamic differences from drug effects on impaired organs e.g. poor ability to respond to CVS, respiratory and CNS depressant agents
Greater incidence of complications e.g. delirium, pneumonia, thrombo-embolism
Longer ICU and hospital stay
Pathophysiological change and Management implications in ESRF
Respiratory:
Prone to pulmonary oedema
Fluid restriction/ positive pressure ventilation as needed
Cardiovascular: Hypertension Dyslipidaemia, Atherosclerosis, Pericarditis Appropriate drug therapy, aim higher MAP targets based on baseline BP Monitor for pericardial effusion
Neurological:
Dialysis disequilibrium
Polyneuropathy myopathy
Low dose dialysis to prevent rapid shifts
Renal:
Low/no urine output
Fluid prescribing/restriction, nutrition depends on dialysis plan
Metabolic: Hyperkalaemia Metabolic acidosis K+ restriction, Caution with K-sparing drugs (ARBs, ACE-Is, Spironolactone)
Mineral & Bone disorders: Secondary hyperparathyroidism, Hyperphosphataemia, Hypocalcaemia Phosphate restriction/binders, Calcitriol and calcium supplementation, Care to prevent fractures
Gastrointestinal: Impaired gastrointestinal motility Peptic ulceration & bleeding Malnutrition Aspiration risk, enteral feeding difficulty Stress ulcer prophylaxis Early feeding
Skin:
Fragile skin
Meticulous pressure area care
Haematological: Anaemia Platelet dysfunction (uraemic) Appropriate transfusion, EPO Bleeding risk, DDAVP may have a role
Immunological:
Increased risk of infection
Antimicrobial prophylaxis/therapy as appropriate
Endocrine:
Thyroid dysfunction
Difficult to interpret TFTs during critical illness
Pharmacological:
Altered clearance of renally excreted medications
Dose adjustment based on GFR, dialysis regime
Vascular access:
Consider choice of site avoiding site of fistula, Monitor fistula function during critical illness
Typical acid base changes in salycilate poisoning
Acid-base status:
Increased anion gap metabolic acidosis
Concomitant normal anion gap metabolic acidosis
Respiratory alkalosis
Decreased delta ratio
Investigations for a snake bite victim:
CK (rhabdmyolysis)
Coags (DIC, or “venom-induced consumption coagulpathy)
FBC (DIC, looking for thrombocytopenia and red cell fragmentation)
Fibrinogen (DIC)
EUC (renal failure)
LFTs (hepatic injury)
Snake Venom Detection Kit
Indications for polyvalent antidote:
Unsure which snake species was involved
SVDK not available
monovalent antivenom not available
the patient has been bitten by multiple different species of unidentified snakes.
Evidence for premedication for antivenom administration:
This is no longer recommended in Australia
polyvalent antidote tends to have a higher rate of anaphylaxis
How do you know your monovalent antivenom is working?
The short answer is, you don’t.
It takes tme for some of the irreversible features to resolve (eg. it takes time to synthesis the coagulation factors which have been depleted)
Giving more antivenom will not improve the situation.
Reasons for altered drug clearance in critically ill
decreased spontaneous degradation
- hypothermia
decreased tissue metabolism
- decreased tissue blood flow
- hypothermia
decreased plasma metabolism
- due to poor hepatic synthetic function, many serum enzymes responsible for drug removal are not synthetised in appropriate quantities
decreased metabolism in the liver
- decreased hepatic blood flow
- cytokine-induced decrease in hepatic metabolism
hepatic injury
- hypothermia leading to diminished enzyme function
-hepatic enzyme inhibition by other drugs
increased metabolism in the liver
- pyrexia leading to increased metabolic rate
- enzyme activation by other drugs
decreased clearance in the urine
- decreased renal blood flow
- decreased glomerular filtration rate
- poor tubular function, decreased active transport
- acute renal injury eg. ATN
decreased clearance in the bile
- biliary stasis
- decreased gut transit leading to recirculation
- increased clearance due to decreased portein binding
thus, increased free fraction, which is exposed to clearance mechanisms
effect of critical illness on enteral drug absorption
- Multiple factors may alter gastrointestinal mucosal absorption including mucosal oedema, disordered gastrointestinal motility and disordered mucosal blood flow
- Gastric emptying / gut motility affected by drugs (opioids. Anticholinergics, antacids, inotropes), enteral nutrition, brain or spinal injury, diabetes
- Incomplete oral medication disintegration or dissolution
- Changes in pH
indications for multiple dose activated charcoal
Amitriptyline Carbamazepine Cyclosporine Dapsone Dextropropopxyphene Digitoxin Digoxin Disopyramide Nadolol Phenobarbital Phenylbutazone Phenytoin Piroxicam Propoxyphene Quinine Sotalol Theophylline
Complications of charcoal administration
Its gross. Patients complain. However, actual vomiting appears to be rare (Isbister et al, 2011)
It may absorb usueful medications as well as the toxin.
It may increase the risk of aspiration (but if it does, then not y much)
Aspirated, it may be more harmful than sterile gastric contents (but if it is, then not by much). In their answer to Question 29 from the second paper of 2010, the college lists direct administration of charcoal into the lung as a valid concern.
It may cause bowel obstruction; this is rare, and usually associated with multiple dose charcoal in patients who are poisoned with an agent which affects gut motility.
Use of dialysis in toxicology:
the drug is easily dialysed:
- small molecule
- water soluble
- not extensively protein bound
- small volume of distribution
The drug produces dialysable matabolites, which are toxic (eg. ethylene glycol)
The toxicity produces an acid-base disturbance which cannot be addressed by any other means (eg. lactic acidosis in cyanide toxicity)
charcoal haemoperfusion indications
Paraquat Parathion Theophylline Carbamazepine Phenytoin Paracetamol Digoxin Diltiazem Metoprolol Colchicine Promethazine Amanita phalloides mushroom toxin (phalloidin)
Risk factors for propofol infusion syndrome
Propofol infusion dose of >4mg/kg/hr for over 48 hrs
Traumatic brain injury
Catecholamine infusion
Corticosteroid infusion
Carnitine deficiency
Low carbohydrate intake: because energy demand is met by lipolysis if carbohydate intake is low, thus leading to the accumulation of free fatty acids.
Children more susceptible than adults - probably because their glycogen store is lower, and they depend on fat metabolism.
Congenital weirdness: Medium-chain acyl CoA dehydrogenase (MCAD) deficiency
Clinical features and laboratory findings in propofol infusion syndrome
Acute bradycardia leading to asystole.
A prelude to the bradycardia is a sudden onset RBBB with ST elevation in V1-V3; Kam’s article has the picture of this ECG.
Arrhythmias
Heart failure, cardiogenic shock
Metabolic acidosis (HAGMA) with raised lactate (and also due to fatty acids)
Rhabdomyolysis, raised CK and myoglobin
Hyperlipidaemia
Fatty liver and hepatomegaly
Coagulpathy
Raised plasma malonylcarnitine and C5-acylcarnitine